DOV ANNOUNCES AMENDED AGREEMENT WITH MERCK & CO. ON ITS NOVEL ANTIDEPRESSANTS

DOV Pharmaceutical, Inc (Nasdaq: DOVP - News) announced that DOV and Merck & Co., Inc. have amended their 2004 license agreement covering the clinical development activities of DOV 21,947 and DOV 216,303. Under the amendment certain development contemplated by the license agreement for DOV 21,947 will initially be undertaken by DOV. In addition, the amendment provides for the possible future expansion of the collaboration with Merck to include an additional triple reuptake inhibitor from DOV's preclinical pipeline if such compound is selected after certain testing has been completed by Merck. The amendment follows review of data from preclinical studies in models of depression and a pilot phase I biomarker study in normal volunteers.

Yahoo News (http://biz.yahoo.com/prnews/050808/nym178.html?.v=14)